Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy (semaglutide) is FDA-approved for chronic weight management, yet not everyone can safely use it. Medical contraindications, drug interactions, and individual risk factors determine eligibility, and some patients require alternative approaches. PlexusDx offers personalized semaglutide therapy through licensed compounding pharmacies, with dosing and formulations tailored to your unique health profile.
Personal or Family History of Thyroid Cancer Disqualifies Wegovy Use
GLP-1 receptor agonists like Wegovy carry a boxed warning for thyroid C-cell tumors based on animal studies. Patients with a personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) cannot take Wegovy because the medication may trigger thyroid cancer growth or recurrence. This restriction applies regardless of how much weight someone needs to lose.
Family history of thyroid cancer also raises concern. If your parents, siblings, or children developed MTC before age 50, you fall into a higher-risk category and should avoid Wegovy entirely. A detailed family history review during consultation helps identify this risk. PlexusDx providers conduct thorough screening to ensure semaglutide is appropriate for your specific genetic and medical background.
Severe Kidney or Liver Disease Requires Medical Caution
Patients with severe kidney disease or end-stage renal failure may accumulate GLP-1 medications in their bloodstream because the kidneys filter these compounds. While mild-to-moderate kidney impairment does not require dose adjustment, severe disease (eGFR below 15 mL/min/1.73m²) warrants close physician oversight or alternative therapies. Liver cirrhosis and decompensated liver disease similarly limit Wegovy safety because the liver metabolizes and processes many medications.
Pancreatitis history—particularly acute or chronic—is a relative contraindication. GLP-1 agonists increase pancreatitis risk in susceptible individuals. Anyone with unexplained severe abdominal pain, chronic pancreatitis, or gallbladder disease should consult their doctor before starting semaglutide. PlexusDx providers assess organ function through lab review and medical history to determine whether compounded semaglutide or an alternative peptide therapy is safer.
Pregnancy, Breastfeeding, and Type 1 Diabetes Create Safety Concerns
Pregnancy is an absolute contraindication for Wegovy and all GLP-1 agonists. Animal studies show potential fetal harm, and human safety data remain insufficient. Women of childbearing age using Wegovy must employ reliable contraception and stop the medication at least two months before attempting pregnancy. Breastfeeding mothers should also avoid GLP-1 therapy because it is unknown whether semaglutide passes into breast milk or affects nursing infants.
Type 1 diabetes patients cannot use Wegovy for weight loss because these medications lower blood sugar and increase hypoglycemia risk in insulin-dependent patients. GLP-1 agonists are designed primarily for type 2 diabetes, not type 1. Patients with type 1 diabetes who need weight loss require insulin adjustment and specialist oversight, not Wegovy. PlexusDx prioritizes safety screening to exclude type 1 diabetics from semaglutide therapy.
Medication Interactions and Allergy Status Affect Eligibility
Patients taking insulin or insulin secretagogues (sulfonylureas, meglitinides) face increased hypoglycemia risk when combining these drugs with Wegovy. Dose reduction of diabetes medications is often necessary, yet many patients do not receive proper dosage adjustment, leading to dangerous blood sugar drops. A known allergy to semaglutide or any GLP-1 receptor agonist is an absolute contraindication. Anyone with a documented severe allergic reaction (anaphylaxis, angioedema) cannot restart or switch to another GLP-1 product.
Oral medications that require food for absorption may interact with GLP-1 therapy because semaglutide slows stomach emptying. Medications like certain antibiotics, birth control pills, or antiretrovirals need adequate absorption timing. Additionally, patients on warfarin or other anticoagulants may experience altered drug levels due to slowed gastric transit, requiring INR monitoring. PlexusDx clinicians review all medications during intake to identify interactions and adjust treatment plans accordingly.
Genetic Predisposition Testing Refines Your Semaglutide Candidacy
Beyond medical contraindications, genetic variation in GLP-1 and other peptide pathways influences how well semaglutide works for you. The PlexusDx Precision Peptide Genetic Test examines 49 peptides and 14 metabolic pathways—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—to predict your response profile. Patients with certain genetic variants may respond better to tirzepatide, combination therapy, or microdose protocols than to standard semaglutide alone.
This genetic insight transforms weight loss from guesswork into precision medicine. Someone with low predicted GLP-1R sensitivity but strong GIPR pathway activation may achieve better results with GLP-Squared (dual semaglutide and tirzepatide compound) or oral tirzepatide. PlexusDx starts treatment after month one of therapy, allowing time to assess initial response before genetic testing guides optimization. The $99 genetic test unlocks 150+ personalized insights to refine your peptide protocol.
How PlexusDx Screens for Contraindications and Offers Alternatives
PlexusDx licensed 503A compounding pharmacies follow the same strict screening protocols as branded Wegovy prescribers. During your initial consultation, providers document personal and family medical history, review current medications, assess kidney and liver function, and screen for pancreatitis or gallbladder disease. If Wegovy-style semaglutide is contraindicated, PlexusDx offers alternative GLP-1 compounds, tirzepatide, or dual peptide protocols tailored to your safety profile and genetics.
Monthly pricing starts at $149 for compounded semaglutide injection, with no insurance required, HSA/FSA eligibility, and availability in all 50 states. If standard semaglutide carries risk for you, tirzepatide injection ($249/mo) or microdose GLP-1 protocol ($129/mo) may be safer options. PlexusDx also offers oral formulations and genetic testing to map your unique peptide response. The goal is effective, personalized weight loss therapy that keeps you safe.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I take Wegovy if I have a family history of thyroid cancer?
No. If any close relative (parent, sibling, child) had medullary thyroid carcinoma or MEN 2 syndrome, Wegovy is contraindicated due to the boxed warning for thyroid C-cell tumors. PlexusDx providers screen for this risk during consultation. If semaglutide is unsafe, alternative peptide therapies may still support weight loss.
Is Wegovy safe if I have type 1 diabetes?
No. Wegovy is not approved for type 1 diabetes weight loss because it increases hypoglycemia risk in insulin-dependent patients. Type 1 diabetics require insulin dose adjustment and specialist care, not GLP-1 agonists for weight management. PlexusDx excludes type 1 diabetics from semaglutide protocols.
Can I use Wegovy while pregnant or breastfeeding?
No. Wegovy is contraindicated in pregnancy due to potential fetal harm and is not recommended during breastfeeding. Women on Wegovy must use reliable contraception and discontinue at least two months before trying to conceive. PlexusDx requires pregnancy safety screening before treatment initiation.
How does PlexusDx pricing compare if Wegovy is not safe for me?
PlexusDx compounded semaglutide injection starts at $149/month with flat pricing (your dose may go up, but your price won't). If semaglutide is contraindicated, tirzepatide injection costs $249/month, or the microdose GLP-1 protocol is $129/month. All are available without insurance across all 50 states.
What is the PlexusDx Precision Peptide Genetic Test and how does it help?
The $99 test examines 49 peptides across 14 pathways—including GLP1R, GIPR, FTO, and MC4R variants—to predict your personalized response to semaglutide, tirzepatide, or combination therapy. This genetic insight available after your first month of treatment helps optimize your protocol for best results and safety.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Which Dose of Ozempic is Best for Weight Loss?
Can I Eat Sugar on Wegovy? Balancing Sweetness and Sustainable Weight Loss